Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.


Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?


Please Try Again {{ error }}

Send my password

An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Brooklyn ImmunoTherapeutics Announces Third Quarter 2021 Financial Results


NEW YORK, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc. (Nasdaq:BTX) (“Brooklyn”), a biopharmaceutical company focused on exploring the role that cytokine, gene editing, and cell therapy can have in treating patients with cancer, blood disorders, and monogenic diseases, today announced financial results for the quarter ended September 30, 2021.

Financial and corporate highlights for the quarter ended September 30, 2021 and subsequently include the following:

  • Transitioned from the NYSE American to the Nasdaq Global Market to better align with industry peers
  • Completed the acquisition of Novellus Therapeutics
  • Appointed Roger Sidhu, M.D. as chief medical officer, Jay Sial as chief administrative officer and Kevin D’Amour, Ph.D. as chief scientific officer.

Howard Federoff, M.D., Ph.D., Brooklyn’s President and Chief Executive Officer, commented, “We continue evolving Brooklyn ImmunoTherapeutics into a platform company with a pipeline of next-generation engineered cellular, gene editing and cytokine products. The acquisition of Novellus has provided us with the full range of MSCs to combine with our licensed mRNA-based cell reprogramming and gene editing technology from Factor Bioscience. We believe this platform technology will yield product candidates in varying stages of development from target selection to research and preclinical, including one in the respiratory area that is in the IND-enabling stage.”

Dr. Federoff continued, “With the addition of key personnel, including both a chief medical officer and a chief scientific officer, we are now appropriately positioned to execute on our ambitious agenda and to begin using our technology to its fullest extent. We believe our future new drug candidates are best suited to address a variety of underserved medical conditions. In addition, we can go confidently about our work knowing that we have also placed a chief administrative officer within the Company to ensure that the business is run with the same precision as the science.”

“We also continue to benefit from a strong balance sheet and a growing in-licensed intellectual property portfolio,” said Dr. Federoff. “As I have indicated before, following the Novellus acquisition, we had approximately $25 million of cash on hand, which we estimate will fund our operations and expansion into 2023. In the meantime, we believe that the transition from the NYSE American to the Nasdaq Global Markets will place us among more of our industry peers, and as a result, attract additional investors who might be more likely to be seeking to invest in a company such as ours.”

“Finally, as we await the readout of our Phase 2b trial for neoadjuvant head and neck cancer with our original asset, IRX-2 (a human-derived mixed cytokine product), during the first half of 2022, we continue investigator-driven trials in a number of additional cancer types and look forward to sharing these outcomes as appropriate,” concluded Dr. Federoff.

Financial Results for Quarter Ended September 30, 2021

Operating expenses for the quarter ended September 30, 2021 were $86.3 million, including $80.5 million of acquired in-process research and development expense related to the Novellus acquisition, compared to $2.0 million of operating expenses for the quarter ended September 30, 2020.

Research and development expenses, excluding the acquired in-process research and development, were $1.5 million for the quarter ended September 30, 2021 compared to $0.9 million in the quarter ended September 30, 2020. Research and development expenses increased due to increased headcount and non-cash stock-based compensation resulting from the issuance of equity awards. Brooklyn expects research and development expenses to continue to grow as it expands its clinical trial activities and gene-editing cell therapy research.

General and administrative expenses were $4.3 million in the third quarter of 2021 compared to $1.1 million during the same period in 2020. The quarter-over-quarter increase in general and administrative expense was primarily related to increased legal, accounting and consulting fees associated with merger and acquisition activity, costs associated with being a publicly traded company, increased headcount, increased insurance expense and increased non-cash stock-based compensation. Brooklyn expects general and administrative expenses to continue to increase in future periods as it increases its business activities and incurs costs associated with being a publicly traded company.

Net loss for the quarter ended September 30, 2021 was $86.1 million, as compared to a net loss of $2.0 million for the quarter ended September 30, 2020.

As of September 30, 2021, Brooklyn had approximately $24.4 million in cash.

About Brooklyn ImmunoTherapeutics

Brooklyn is focused on exploring the role that cytokine, gene editing, and cell therapy can have in treating patients with cancer, blood disorders, and monogenic diseases.

Brooklyn’s most advanced program is IRX-2, a human cell-derived cytokine therapy, studying the safety and efficacy of IRX-2 in patients with head and neck cancer in Phase 2B. In a Phase 2A clinical trial in head and neck cancer, IRX-2 demonstrated an overall survival benefit. Additional studies are either underway or planned in other solid tumor cancer indications.

Brooklyn has multiple next-generation cell and gene-editing therapies in preclinical development for various indications including acute respiratory distress syndrome, solid tumor indications, as well as in vivo gene-editing therapies for rare genetic diseases. For more information about Brooklyn and its clinical programs, please visit



September 30, 2021 December 31, 2020
ASSETS (unaudited)
Current assets:
Cash $ 24,381,831 $ 1,630,455
Tax receivable 23,303 -
Prepaid expenses and other current assets 1,353,183 102,322
Total current assets 25,758,317 1,732,777
Property and equipment, net 547,006 594,106
Right-of-use assets - operating leases 2,665,828 2,092,878
Goodwill 2,043,747 2,043,747
In-process research and development 6,860,000 6,860,000
Investment in NoveCite 1,000,000 -
Security deposits and other assets 519,467 453,252
Total assets $ 39,394,365 $ 13,776,760
Current liabilities:
Accounts payable $ 996,262 $ 1,275,223
Accrued expenses 2,128,493 1,051,020
Loans payable 410,000 410,000
PPP loan, current - 115,972
Operating lease liabilities, current 408,125 273,217
Other current liabilities 617,661 -
Total current liabilities 4,560,541 3,125,432
Contingent consideration 19,360,000 20,110,000
Operating lease liabilities, non-current 2,410,667 1,905,395
PPP loan, non-current - 193,933
Other liabilities 22,863 22,863
Total liabilities 26,354,071 25,357,623
Stockholders’ and members’ equity (deficit):
Class A membership units - 23,202,005
Class B membership units - 1,400,000
Class C membership units - 1,000,000
Common units - 197,873
Series A convertible preferred stock 781 -
Common stock, $0.005 par value, 100,000,000 shares authorized; 52,043,818 issued and outstanding at September 30, 2021; no shares issued and outstanding at December 31, 2020. 260,219 -
Additional paid-in capital 164,010,804 -
Accumulated deficit (151,231,510 ) (37,380,741 )
Total stockholders’ and members’ equity (deficit) 13,040,294 (11,580,863 )
Total liabilities and stockholders’ and members’ equity (deficit) $ 39,394,365 $ 13,776,760


Three months ended September 30, Nine months ended September 30,
2021 2020 2021 2020
Operating expenses:
Research and development 1,466,652 923,529 8,379,062 2,299,669
Acquired in-process research and development 80,537,551 - 80,537,551 -
General and administrative 4,258,178 1,084,057 10,515,088 2,741,652
Transaction costs - - 5,765,407 -
Change in fair value of contingent consideration 70,000 - (750,000 ) -
Total operating expenses 86,332,381 2,007,586 104,447,108 5,041,321
Loss from operations (86,332,381 ) (2,007,586 ) (104,447,108 ) (5,041,321 )
Other income (expenses):
Loss on sale of NTN assets - - (9,648,173 ) -
Other income (expense), net 277,069 (12,559 ) 252,318 (31,482 )
Total other income (expenses), net 277,069 (12,559 ) (9,395,855 ) (31,482 )
Net loss (86,055,312 ) (2,020,145 ) (113,842,963 ) (5,072,803 )
Series A convertible preferred stock dividend - - (7,806 ) -
Net loss attributable to common stockholders $ (86,055,312 ) $ (2,020,145 ) $ (113,850,769 ) $ (5,072,803 )
Net loss per common share - basic and diluted $ (1.70 ) $ (0.11 ) $ (2.82 ) $ (0.29 )
Weighted average shares outstanding - basic and diluted 50,543,982 17,626,806 40,362,440 17,570,973


For the nine months ended
September 30,
2021 2020
Cash flows used in operating activities:
Net loss $ (113,842,963 ) $ (5,072,803 )
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization 92,754 72,909
Stock-based compensation 3,301,697 68,202
Amortization of right-to-use asset 242,849 -
Transaction costs - shares to Financial Advisor 5,765,407 -
Loss on sale of NTN assets 9,648,173 -
Loss on disposal of fixed assets 12,626 -
Gain on forgiveness of PPP loan (309,905 ) -
Acquired in-process research and development 80,537,551 -
Change in fair value of contingent consideration (750,000 ) -
Changes in operating assets and liabilities:
Account receivable 4,680 -
Prepaid expenses and other current assets (1,109,270 ) (69,240 )
Security deposits and other non-current assets (31,496 ) (84,914 )
Accounts payable and accrued expenses 5,881 (1,392,925 )
Operating lease liability (225,618 ) (2,356 )
Other liabilities - 17,842
Net cash used in operating activities (16,657,634 ) (6,463,285 )
Cash flows used in investing activities:
Purchase of property and equipment (6,860 ) (26,177 )
Purchase of NTN, net of cash acquired 147,262 -
Purchase of Novellus, net of common stock issued and cash acquired (22,853,608 ) -
Proceeds from the sale of NTN assets, net of cash disposed 118,594 -
Net cash used in investing activities (22,594,612 ) (26,177 )
Cash flows provided by financing activities:
Net proceeds of common stock issued to Lincoln Park 52,025,414 -
Proceeds from the exercise of stock options 10,202 -
Proceeds from loans payable - 309,905
Proceeds from the collection of subscription receivable - 275,000
Repayment of NTN’s PPP loan (531,994 ) -
Proceeds from sale of members’ equity 10,500,000 3,858,750
Net cash provided by financing activities 62,003,622 4,443,655
Net increase (decrease) in cash and cash equivalents 22,751,376 (2,045,807 )
Cash and cash equivalents at beginning of period 1,630,455 5,100,819
Cash and cash equivalents at end of period $ 24,381,831 $ 3,055,012

Forward-Looking Statements

The third through sixth paragraphs of this release and the second and third paragraphs under the heading “Financial Results for Quarter Ended September 30, 2021” contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are intended to be covered by the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are any statements that are not statements of historical fact and may be identified by terminology such as “believe,” “could,” “estimate,” “expect,” “plan,” “possible,” “potential,” “project,” “will” or other similar words. Forward-looking statements are based on current beliefs and assumptions that are subject to risks and uncertainties and are not guarantees of future performance. Actual results could differ materially from those stated or implied in any forward-looking statement as a result of various factors, including, but not limited to, uncertainties related to: (i) the evolution of Brooklyn’s business model into a platform company focused on cellular, gene editing and cytokine programs; (ii) Brooklyn’s ability to successfully, cost-effectively and efficiently develop its technology and products; (iii) Brooklyn’s ability to successfully commence clinical trials of any products on a timely basis or at all; (iv) Brooklyn’s ability to successfully fund and manage the growth of its development activities; (v) Brooklyn’s ability to obtain regulatory approvals of its products for commercialization; and (vi) uncertainties related to the impact of the COVID-19 pandemic on the business and financial condition of Brooklyn, including on the timing and cost of its clinical trials. You should not rely upon forward-looking statements as predictions of future events. The forward-looking statements made in this communication speak only as of the date on which they were made, and Brooklyn does not undertake any obligation to update the forward-looking statements contained herein to reflect events that occur or circumstances that exist after the date hereof, except as may be required by applicable law or regulation. Factors that may impact Brooklyn's success are more fully disclosed in Brooklyn's periodic public filings with the U.S. Securities and Exchange Commission, particularly under the heading “Risk Factors” in Brooklyn’s Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2021.

Investor Relations Contact:

Media Contact:
Jules Abraham

Primary Logo